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Obesity is a major public health issue worldwide.
Understanding how the brain controls appetite offers
promising inroads toward new therapies for obesity.
Peptide YY (PYY) and glucagon-like peptide 1 (GLP-
1) are coreleased postprandially and reduce appetite
and inhibit food intake when administered to
humans. However, the effects of GLP-1 and the
ways in which PYY and GLP-1 act together to modu-
late brain activity in humans are unknown. Here, we
have used functional MRI to determine these effects
in healthy, normal-weight human subjects and com-
pared them to those seen physiologically following a
meal. We provide a demonstration that the combined
administration of PYY3-36 and GLP-17-36 amide to
fasted human subjects leads to similar reductions in
subsequent energy intake and brain activity, as
observed physiologically following feeding.
INTRODUCTION
Obesity poses a major public health issue in modern societies.
Pharmacological treatments have been disappointing and have
been limited by CNS and cardiovascular side effects. Promis-
ingly, anorectic gut hormones, including peptide YY (PYY) and
glucagon-like peptide 1 (GLP-1), have recently emerged as
potential therapeutic targets for obesity.
Both PYY and GLP-1 are released postprandially into the
circulation by the enteroendocrine L cells of the gut. Peripheral
administration of PYY3-36 to humans leads to marked inhibition
of food intake (Batterham et al., 2002; Sloth et al., 2007). A
range of studies has also demonstrated that peripheral adminis-
tration of GLP-17-36 amide to humans leads to a dose-dependent
reduction in appetite and ad libitum energy intake (Verdich
et al., 2001). Recently there has been interest in investigating
how these satiety factors act together to physiologically regulate
postprandial satiety (Neary et al., 2005). It is likely that these
hormones act via the CNS (Batterham et al., 2002; Turton
et al., 1996), although the mechanisms by which GLP-1, in addi-700 Cell Metabolism 14, 700–706, November 2, 2011 ª2011 Elseviertion to PYY and GLP-1 in combination, mediate their anorectic
effect in humans are unknown.
Blood oxygen level-dependent (BOLD) functional magnetic
resonance imaging (fMRI) has recently been used as a tool to
investigate the changes in brain activity associated with differ-
ences in nutritional status in humans. Activity of reward systems
in the brain is increased in the fasted state compared to the fed
state with presentation of food-relevant stimuli (LaBar et al.,
2001). However, there are only a few reports on the use of
fMRI for characterization of brain activity following the systemic
administration of hormones affecting appetite in humans (Baicy
et al., 2007; Batterham et al., 2007; Farooqi et al., 2007; Malik
et al., 2008; Rosenbaum et al., 2008). Intravenous infusion of
PYY3-36 to human subjects modulates activity in brain regions
mediating appetitive behavior and leads to reduced food intake
(Batterham et al., 2007). However, there have been no human
fMRI studies investigating effects of administration of GLP-1 or
coadministration of PYY and GLP-1 on brain activity in humans.
In this work, we have used BOLD fMRI to investigate the
changes in brain activity following PYY3-36 or GLP-17-36 amide
(either as single or combined administration) in fasted healthy
humansubjects andcompared the effects to those seennaturally
following a meal. We demonstrate that following a meal, there is
a reduction in subsequent energy intake and BOLD fMRI signal
in several brain regions that have been previously implicated in
responses to food reward. We show that coadministration of
PYY3-36 and GLP-17-36 amide to fasted human subjects results
in a reduction in BOLD fMRI signal and in subsequent energy
intake similar to that occurring following feeding. Together,
these findings provide evidence in humans that PYY3-36 and
GLP-17-36 amide in combination result in changes in brain activity,
which are similar to those observed after a meal. In combination,
PYY3-36 and GLP-17-36 amide may well act via a final common
pathway as key mediators of postprandial satiety.
RESULTS
Both Feeding and the Infusion of PYY3-36 and
GLP-17-36 amide Reduce Subsequent Energy Intake
Following saline, PYY3-36, or GLP-17-36 amide (either as single
or combined administration) in fasted human subjects, weInc.
Figure 1. Study Protocol
Following an overnight fast, 16 healthy, normal-weight subjects each received
the following interventions, in random order, over 5 separate study days
in a single-blinded fashion: (1) 90 min saline infusion (fasted saline, control
visit); (2) standard breakfast, then 90 min saline infusion (fed saline); (3) 90 min
PYY3-36 infusion at 0.3 pmol/kg/min; (4) 90 min GLP-17-36 amide infusion at
0.8 pmol/kg/min; (5) 90 min combined PYY3-36 and GLP-17-36 amide infusion, at
0.3 pmol/kg/min and 0.8 pmol/kg/min, respectively. On each visit, subjects
underwent a 60 min fMRI scan, which commenced 20 min after the start of the
infusion. During the fMRI scan, a picture processing task was performedwhere
images of food and nonfood were shown. The mean percent change in BOLD
signal in prespecified brain ROIs when viewing images of food compared to
nonfood were determined for each study day. An ad libitum buffet meal was
served immediately after the infusion on all study days in order to measure
energy intake. Blood sampling (for PYY3-36 and GLP-17-36 amide) and assess-
ments of appetite (based on VAS after direct questioning) was performed. One
subject was excluded from analysis due to excessive head movement during
the scans, leaving data from 15 subjects for analysis.
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PYY3-36 and GLP-17-36 Inhibit CNS Appetite Centersmeasured ad libitum energy intake during a buffet lunch (Fig-
ure 1). Plasma levels of PYY3-36 or GLP-17-36 amide, which are
the active forms of these hormones, increased on infusion
(Figures 2A and 2B). We compared the effects of PYY3-36 and
GLP-17-36 amide to those seen naturally following a breakfast
meal. Consumption of a standard breakfast by subjects before
saline infusion led to a 23.5% ± 8.3% reduction in energy intake
during the subsequent ad libitum buffet lunch compared to when
subjects received only saline infusion. Infusion of PYY3-36,
GLP-17-36 amide, or combined PYY3-36 and GLP-17-36 amide to
fasted subjects resulted in 12.3% ± 11.2%, 15.7% ± 7.5%,
and 27.0% ± 9.4% reductions in energy intake, respectively,
compared to when subjects received saline infusion (Figure 2C).
There were no order effects on energy intake across visits (data
not shown).
We compared the additive effects of single infusions of
PYY3-36 and GLP-17-36 amide with combined infusion of PYY3-36
and GLP-17-36 amide on energy intake at the ad libitum lunch (Fig-
ure 2D). The summed reduction in energy intake by each of the
single hormone infusions was comparable with the reduction
after the combined infusion.
Effects of Feeding or Infusion of PYY
and GLP-1 on Appetite
Visual analog scores (VAS) of appetite by subjects confirmed
that consumption of the standard breakfast or combinedCell Minfusion of PYY3-36 and GLP-17-36 amide reduced hunger and
increased their sense of ‘‘fullness’’ (Figure S1). There was no
correlation between nausea and energy intake during the ad libi-
tum buffet meal (p = 0.23, r2 = 0.02, Figure S1F).
Brain Activation with Presentation of Food-Salient
Visual Stimuli
We assessed brain activation with presentation of food-salient
images using BOLD fMRI. We a priori chose to test six regions
of interest (ROIs) (amygdala, caudate, insula, nucleus accum-
bens, orbitofrontal cortex [OFC], and putamen) based on
previous research in the field (Batterham et al., 2007; Farooqi
et al., 2007; Fletcher et al., 2010; LaBar et al., 2001; Malik et al.,
2008). We found that when subjects infused with saline (in either
the fasted or fed state) viewed images of food, there was greater
BOLD signal in these regions compared with when nonfood
imageswere viewed (Figure 3A). Awhole-brain cluster-wise anal-
ysis supported the selection of these ROIs (Table S1).
Feeding, PYY, and GLP-1 Administration Reduce Brain
Activation by Food Images
We first tested the effects of feeding, PYY3-36, GLP-17-36 amide,
and combined PYY3-36 and GLP-17-36 amide on changes in
mean percent BOLD signal in the total brain volume represented
by the six a priori selected ROIs (Figure 3B). When fasted
subjects viewed images of food compared with when they
viewed images of nonfood, there was a significant reduction
(p < 0.001) in the mean percent BOLD fMRI signal change after
administration of PYY3-36 or after coadministration of PYY3-36
and GLP-17-36 amide compared to when subjects were fasted
and received saline infusion (control). There was a nonsignificant
reduction in the mean percent BOLD signal change in the
selected ROIs following feeding or after GLP-17-36 amide adminis-
tration compared to when subjects were fasted and received
saline infusion.
There was no observed correlation between changes in
nausea ratings and the mean percent change in BOLD signal
for any of the interventions (data not shown). Similarly, there
was no observed correlation between the mean percent change
in BOLD signal and subsequent energy intake during the ad libi-
tum buffet lunch for any of the interventions (data not shown).
We next examined the mean percent change in BOLD
signal (when subjects viewed images of food compared to
when they viewed images of nonfood) after feeding, PYY3-36,
GLP-17-36 amide, or combined PYY3-36 and GLP-17-36 amide infu-
sion across the individual a priori selected ROIs (left and right
hemisphere data combined). We compared this to the mean
percent change in BOLD signal when subjects were fasted and
received saline (control). There were similar reductions in mean
percent change in BOLD signal for all of the ROIs studied
following feeding or gut hormone administration, compared to
when subjects were fasted and received saline (Figure 4). In
addition, individual analysis of left and right hemisphere ROIs
showed that reductions in mean percent BOLD signal change
for PYY3-36 versus fasted saline in the left nucleus accumbens
(p = 0.01) and the left OFC (p = 0.02) and for GLP-17-36 amide
versus fasted saline in the right insula (p = 0.049) were significant.
The reduction in mean percent BOLD signal change with the
combined infusion of PYY3-36 and GLP-17-36 amide was similaretabolism 14, 700–706, November 2, 2011 ª2011 Elsevier Inc. 701
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Figure 2. Analysis of Plasma PYY3-36 and GLP-17-36 amide Levels and Mean Ad Libitum Energy Intake
(A–D) On each study visit, the hormone infusion was administered between t = 0 and t = 90 min. Shown are plasma PYY3-36 levels (A) and plasma GLP-17-36 amide
levels (B). Data are shown as mean ± SEM for 15 subjects. An ad libitum buffet meal was served immediately after the infusion in order to measure energy intake
on all study days. Shown are the energy intake during the buffet meal following each infusion (C) and the reduction in energy intake during the buffet meal for each
infusion versus the fasted saline infusion and also the sum of the individual effects of PYY3-36 and GLP-17-36 amide in reducing energy intake (sum of PYY and
GLP-1) (D). Data are shown asmean ± SEM, grouped for 15 subjects. **p < 0.01 versus fasted saline. ***p = 0.0001 versus fasted saline. Abbreviations: EI, energy
intake; kJ, kilojoules; PYY, PYY3-36; GLP-1, GLP-17-36 amide. See also Figure S1.
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PYY3-36 and GLP-17-36 Inhibit CNS Appetite Centersto the summed reduction in mean percent BOLD signal changes
after individual administrations of the two hormones (Figure S2).
DISCUSSION
We found that coadministration of PYY3-36 andGLP-17-36 amide to
subjects fasted overnight resulted in similar reductions in ad
libitum energy intake during a subsequent buffet lunch as in
subjects who had been fed a standard breakfast. Single infu-
sions of either PYY3-36 or GLP-17-36 amide resulted in smaller
reductions in ad libitum energy intake. The summed effects of
the single hormones (PYY3-36 or GLP-17-36 amide) were similar
to the reduction in energy intake following combined PYY3-36702 Cell Metabolism 14, 700–706, November 2, 2011 ª2011 Elsevierand GLP-17-36 amide infusion; coadministration of PYY3-36 and
GLP-17-36 amide did not appear to lead to loss of effect of
either individual hormone. We have shown that combined gut
hormone infusion of PYY3-36 and GLP-17-36 amide results in
levels of modulation of brain activity similar to those observed
following their summed effects after single infusion. This is
consistent with expectations based on endogenous physio-
logical responses observed postprandially, whereby several
anorectic gut hormones are cosecreted and are thought to act
together to limit further food intake.
We have presented data showing the modulation of BOLD
fMRI signal by feeding within six a priori selected ROIs (amyg-
dala, caudate, insula, nucleus accumbens, OFC, and putamen).Inc.
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Figure 3. Modulation of BOLD Signal across Brain ROIs
(A andB)Duringeach infusion, aBOLD fMRI scanwasperformed, incorporating
a picture processing task where images of food and nonfood were shown.
For the fastedsalineand fedsaline infusions, awhole-brainmapofbrain regions
activated (z-statistics) by food images (compared with nonfood images) is
shown (A). Z indicates distance (mm) superior or inferior to the intercommissural
plane in standard stereotactic space. Clusters were thresholded by means
of parametric testing at the level of spatially contiguous suprathresholded
clusters, simultaneously controlling the family-wise probability of type 1 error at
p< 0.05, corrected. ThemeanpercentBOLDsignal change (food imagesminus
nonfood images) across all six ROIs studied (amygdala, insula, caudate,
nucleus accumbens, OFC, and putamen), is shown for each of the interventions
(B). Data are shown as mean ± SEM, grouped for 15 subjects. Abbreviations:
PYY, PYY3-36; GLP-1, GLP-17-36 amide; **p < 0.01; ***p < 0.001.
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PYY3-36 and GLP-17-36 Inhibit CNS Appetite CentersThese were based on previous studies (Batterham et al., 2007;
Farooqi et al., 2007; Fletcher et al., 2010; LaBar et al., 2001;Malik
et al., 2008) and on our derived functional group activation maps
to inform the particular choice of anatomical masks of the task-
related regions. As predicted, our data demonstrated that in
each of the six brain reward ROIs, viewing images of food was
associated with a greater BOLD fMRI signal than viewing
nonfood images in the fasted state. Consumption of a standard
breakfast reduced this brain activation, extending earlier obser-
vations (LaBar et al., 2001). Activation of the insula was most
sensitive to modulation by consumption of a meal.
We then assessed the change in BOLD signal following infu-
sion of PYY3-36 and GLP-17-36 amide, either singly or in combina-
tion, in fasted subjects. When PYY3-36 alone was infused in the
fasted state, the pattern of signal change in brain reward ROIs
was similar to that observed after feeding, with consistent reduc-
tions in mean percent BOLD signal change across all brain
reward ROIs. Reductions in signal change were prominent in
the insula, left nucleus accumbens, and left OFC. Changes in
OFC activation were also reported in an earlier investigation of
PYY effects (Batterham et al., 2007). In that study, subsequent
food intake was predicted by the modulation of OFC signalCell Mwith PYY3-36 infusion, but not with saline infusion after fasting,
when subsequent food intake was better correlated with
changes in hypothalamic signal. It was postulated that the pres-
ence of PYY3-36 switches regulation of food intake from a
homeostatic brain region (hypothalamus) to a hedonic region
(OFC). However, differences in methodology used (our study
used task-activated BOLD fMRI data, whereas Batterham et al.
tested for changes in resting-state BOLD fMRI) confounds direct
comparisons between the studies.
Analysis of the effects of GLP-17-36 amide on human brain acti-
vation revealed that infusion of GLP-17-36 amide alone led to
consistent reductions in mean percent BOLD signal change
compared with fasted saline across all of the selected ROIs,
with the greatest change in the right insula.
We also characterized the combined effects of infusion of
PYY3-36 and GLP-17-36 amide on brain activity. We found consis-
tent reductions in mean percent BOLD signal change relative to
infusion of saline across all of the selected ROIs, similar to those
observed following a meal. As with GLP-17-36 amide alone, the
insula appeared particularly sensitive to hormonal modulation.
Consistent with effects on ad libitum energy intake, summation
of the effect of each single hormone in reducing mean percent
BOLD signal change was comparable with the reduction in
mean percent BOLD signal change after the combined infusion
of PYY3-36 and GLP-17-36 amide. This provides evidence in
humans that the actions of PYY3-36 and GLP-17-36 amide on brain
responses to food-salient stimuli are additive, explaining the
way in which gut hormones cosecreted physiologically after
meals may work in concert to limit further food intake and cause
satiety. Furthermore, the lack of any obvious differential activa-
tion pattern between PYY3-36 and GLP-17-36 amide suggests
that these hormones may be acting at the level of higher reward
centers via a final common pathway.
We used the full dimension of the functional imaging dataset to
generate a priori knowledge of where activations were expected
in the picture processing task—an approach that, as with all
group-based fMRI analyses, possesses the inherent limitation
of assuming that (during ROI analysis) the estimated activated
areas are the same for each contributing individual subject.
Furthermore, because the whole brain map of brain regions acti-
vated by food images (compared with nonfood images) was
generated from the fasted saline and fed saline visits, a further
limitation lies in the assumption that these same brain regions
would be modulated by infusion of PYY3-36 and GLP-17-36 amide.
It is of interest to consider our findings in relation to other fMRI
studies that have explored the neuroendocrinology of appetite.
In two congenitally leptin-deficient human subjects, daily subcu-
taneous leptin replacement reduced BOLD fMRI activation when
viewing food versus nonfood images in the nucleus accumbens,
caudate, putamen, and globus pallidus (Farooqi et al., 2007). We
found similar activation changes following infusion of PYY3-36
and GLP-17-36 amide. However, in our study the most significant
reductions in mean percent BOLD signal change following infu-
sion of PYY3-36 and GLP-17-36 amide were in the insula, left
nucleus accumbens, and left OFC. This implies that leptin, com-
pared with PYY and GLP-1, modulates distinct neural networks.
We speculate that this may be related to the longer-term
anorectic signaling by the adipokine leptin, relative to the more
acute anorectic effects of postprandially released gut hormones.etabolism 14, 700–706, November 2, 2011 ª2011 Elsevier Inc. 703
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Figure 4. Modulation of BOLD Signal across Brain ROIs by Feeding or Either Individual or Combined Gut Hormone Infusions
(A–D) Subjects underwent a 90 min infusion of saline (fasted saline) as a control. They also had four further infusions: saline after a standard breakfast (A), PYY3-36
after an overnight fast (B), GLP-17-36 amide after an overnight fast (C), and combined PYY3-36 + GLP-17-36 amide after an overnight fast (D). During each infusion,
a BOLD fMRI scan was performed, incorporating a picture processing task where images of food and nonfood were shown. The mean percent BOLD signal
change when subjects viewed images of food compared with when they viewed images of nonfood is shown for each of the infusions administered as
a comparison with the fasted saline infusion: *p = 0.015 for fed saline < fasted saline and p = 0.012 for PYY + GLP-1 < fasted saline. **p = 0.005 for PYY < fasted
saline. Data are shown for individual ROIs (amygdala, insula, caudate, nucleus accumbens [N Acc], OFC, and putamen), combined for left and right hemispheres
and grouped for 15 subjects, shown as mean ± SEM. Abbreviations: PYY, PYY3-36; GLP-1, GLP-17-36 amide. See also Figure S2.
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PYY3-36 and GLP-17-36 Inhibit CNS Appetite CentersOur results are also interesting in relation to a previous study
investigating the effects of ghrelin, the only known gut hormone
which acutely increases food intake, on brain activity in normal-
weight humans (Malik et al., 2008). Intravenous ghrelin infusion
increased BOLD activation when subjects viewed images of
food compared to when they viewed images of nonfood in the
amygdala, OFC, insula, visual areas, and striatum. Intravenous
ghrelin infusion also resulted in increased food intake compared
with saline infusion. By contrast, in our study, the gut hormones
PYY3-36 and GLP-17-36 amide, which acutely inhibit food intake,
resulted in a reduction in mean percent BOLD signal change in
these ROIs. Collectively, our results and those of Malik et al.
suggest that certain brain regions form CNS networks, which
when activated by ghrelin mediate hunger and when inhibited
by the anorectic gut hormones PYY3-36 and GLP-17-36 amide
mediate satiety.704 Cell Metabolism 14, 700–706, November 2, 2011 ª2011 ElsevierThe hypothalamus and certain brainstem nuclei are also
known to be important in the homeostatic control of food intake.
However, in a separate voxel-wise analysis, we did not observe
significant responses in these regions with our visual stimula-
tions (data not shown). Previous similar studies failed to observe
changes in hypothalamic activation (Malik et al., 2008) or
provided no comment on it (Farooqi et al., 2007), although other
BOLD fMRI investigations have quantified hypothalamic signal
(Batterham et al., 2007; Fletcher et al., 2010). Only one has
reported on brainstem activation (Batterham et al., 2007).
Approaches that control for effects ofmotion of brainstem during
the cardiorespiratory cycle could enable the study of activation
responses in future work (Pattinson et al., 2009). The small size
of the hypothalamus (approximately 5 mm in diameter) limits
its resolution using fMRI acquisition parameters applied in our
study. Additionally, magnetic susceptibility signal loss due toInc.
Cell Metabolism
PYY3-36 and GLP-17-36 Inhibit CNS Appetite Centersthe air-tissue interface of the adjacent sinuses limits assessment
of any hypothalamic signal changes.
In summary, we have characterized the effects of single and
combined administration of PYY3-36 andGLP-17-36 amide on brain
BOLD fMRI activations in humans. We have shown that
combined infusion of PYY3-36 and GLP-17-36 amide leads to an
anorectic effect similar to that observed following a meal. In
keepingwith this, combined administrationmodulates brain acti-
vations implicated in appetite control to an extent similar to that
observed physiologically after a meal. These findings provide
direct evidence that the combined action of gut hormones
including PYY3-36 and GLP-17-36 amide in the brain could explain
postprandial satiety.
EXPERIMENTAL PROCEDURES
Peptides
Synthetic human PYY3-36 and GLP-17-36 amide were purchased from Bachem
(St. Helens, UK) and prepared for human administration as previously
described (Neary et al., 2005).
Subjects
Sixteen healthy right-handed subjects (11 male and 5 female, mean age 29.5
years, range 21–36 years, mean body mass index 22.1 kg/m2, range 18.3–
25.1 kg/m2) were recruited through advertisement and assessed to be healthy
during a screening visit with a full medical history, routine blood tests, and
12-lead electrocardiogram. Exclusion criteria were smoking, substance
abuse, eating disorders, regular medication (except for oral contraceptives),
pregnancy, and medical or psychiatric illness. The study was approved by
the St. Mary’s Research Ethics Committee (reference number 09/H0712/4)
and performed in accordance with the Declaration of Helsinki. Full informed
consent was obtained from all subjects prior to enrolment in the study. One
male subject was excluded from the study after recruitment due to excessive
head movement during the MRI scans, resulting in complete data from 15
subjects for analysis.
Study Protocol
All subjects attended for six scan visits. Each visit was separated by at least
3 days. On their first visit, subjects always received an infusion of saline after
an overnight fast. This protocol was identical to that used for the subsequent
visits, and was intended to acclimatize the subject to the experimental proce-
dures. Results from this acclimatization saline visit are not included in the
analysis. During this acclimatization visit, a structural brain scan was obtained
to exclude organic brain disease.
Over the following five study visits, following an overnight fast, subjects
received each of the following interventions, in a single-blinded randomized
fashion (Figure 1):
(1) A 90 min saline infusion (fasted saline, control visit).
(2) Standard breakfast, then a 90 min saline infusion (the fed saline visit).
(3) A 90 min PYY3-36 infusion at 0.3 pmol/kg/min.
(4) A 90 min GLP-17-36 amide infusion at 0.8 pmol/kg/min.
(5) A 90 min combined PYY3-36 and GLP-17-36 amide infusion at
0.3 pmol/kg/min and 0.8 pmol/kg/min, respectively.
The doses of PYY3-36 and GLP-17-36 amide were determined from previous
human studies, which had shown that they would likely cause a significant
reduction in energy intake but also would be well tolerated without side effects
(Neary et al., 2005; Verdich et al., 2001).
Subjects fasted and drank only water from 22:00 hr the night before each
study visit. They were asked to standardize their diet, abstain from alcohol,
and avoid strenuous exercise for 24 hr prior to each visit. After arrival at
09:00 hr (t = 90 min), peripheral venous cannulae were inserted in both fore-
arms (one for infusion and one for blood sampling). On their fed visit, subjects
ate a standard 2500 KJ breakfast (see Energy Intake) in its entirety between
09:30 and 09:50 hr (t =60 to40min). At 10:30 hr (t = 0 min), they were takenCell Minto the scanning room, and a 90 min infusion of saline or gut hormone
commenced.
A MEDRAD MR Injector Spectris Solaris EP (Medrad, Indianola, PA) pump
was used to deliver the infusions at a constant rate of 54ml/hr. Vials of
peptide were dissolved in 2.5 ml vehicle. Blood samples were collected at
t = 60, 0, 15, 30, 45, 60, 75, 90, and 120 min into lithium heparin-coated
tubes containing 1500 kallikrein inhibitor units (0.15 ml) aprotinin (Trasylol,
Bayer Schering Pharma, Berlin). Samples immediately underwent centrifuga-
tion, after which plasma was promptly separated and stored at 20C until
analysis.
At t = 60, 0, 90, and 120 min, subjects completed a series of 100 mm VAS
that rated five food-related sensations (hunger, nausea, pleasantness to eat,
howmuch one could eat, fullness) and four nonfood-related sensations (sleep-
iness, irritability, anxiety, and warmth).
The pulse and blood pressure of each subject was measured at t = 60, 0,
15, 30, 60, 75, 90, and 120 min. Blood glucose was checked on the samples
taken at t = 60, 0, 30, 60, 90, and 120 min with an Optimum Exceed blood
glucose monitor (Abbott Diabetes Care, Maidenhead, Berks).
Twenty minutes after the start of the infusion, a 60 min fMRI scan was per-
formed. At the end of the scan, subjects stayed in the scanner room for a further
10 min until the infusion was stopped at t = 90 min. Subjects were then imme-
diately served a meal that was provided in excess (see Energy Intake) and
asked to eat until comfortably full. Water was freely available. Subjects could
leave at t = 120 min.
Energy Intake
The standard breakfast served to subjects during one of the fMRI study visits
(2500 kJ) consisted of twomedium slices of wholemeal bread, 20 g strawberry
jam, 20 g margarine, two slices of Swiss cheese, 40 g bran flakes, 170 g milk,
and 220 g orange juice. Subjects were asked to consume the entire breakfast
within 20 min.
The ad libitum buffet meal was served in privacy for 20 min and consisted of
either a mild chicken tikka curry with rice (628 kJ/100 g) or a vegetarian option
of tomato and mozzarella pasta (507 kJ/100 g). Each subject had previously
decided on their choice of meal during their screening visit and was subse-
quently served the same meal during each of their study visits. Food was
weighed pre- and postconsumption. Energy intake was calculated from the
weight of food consumed.
Plasma Hormone Assays
PYY3-36 immunoreactivity was measured with a commercial radioimmuno-
assay (Millipore) (Adam et al., 2005).
Active GLP-1 (GLP-17-36 amide and GLP-17-37) immunoreactivity was mea-
sured with a commercially available ELISA kit (Millipore) (King et al., 2011).
Visual Analog Scores
Changes in VAS ratings on a 100 mm scale were assessed for each visit.
Statistical Analysis
Grouped data are represented as the mean ± SEM. Comparisons of energy
intake and ratings of meal palatability were by repeated-measures ANOVA
with Tukey’s multiple comparison posttest. VAS scores were adjusted for
baseline and differences between t = 0 min and t = 90 min (the duration of
the infusion) were compared by repeated-measures nonparametric
Friedman’s test with Dunn’s multiple comparison posttest. Linear regression
analysis was performed to assess correlation between nausea and energy
intake over the whole study. Comparisons of plasma gut hormone levels
during the infusion period (plasma samples from t = 15–90 min inclusive)
were by repeated-measures ANOVA with Tukey’s multiple comparison
posttest. The threshold for statistical significance in each case was set
at p < 0.05. Analyses were performed using Prism version 5.01 software
(GraphPad Software, San Diego, CA).
Functional MRI
T2*-weighted, dual-echo, echo-planar images sensitive to BOLD contrast
were acquired continuously on a 3T Siemens Tim Trio scanner with a 32-
channel head coil (Siemens Healthcare, Erlangen, Germany).etabolism 14, 700–706, November 2, 2011 ª2011 Elsevier Inc. 705
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During the fMRI picture processing task, images of foods and nonfood items
were projected as previously described (Beaver et al., 2006).
Functional MRI Analysis
Using FSL software (http://www.fmrib.ox.ac.uk/fsl/), we estimated the differ-
ence in regional mean BOLD signal intensity between periods of subject expo-
sure to palatable food images in relation to balanced exposure to periods of
nonfood images, at each of six prespecified ROIs bilaterally—amygdala,
caudate, insula, nucleus accumbens, OFC, and putamen—using an in-house
MRI atlas (Tziortzi et al., 2011). We computed the mean percent BOLD signal
change across each ROI by scaling the relevant General Linear Model contrast
parameter estimate with the peak-to-peak regressor amplitude and normal-
izing this ‘‘signal change’’ factor with the global image mean.
Further details about methodology of peptide administration, plasma
hormone quantification, fMRI scanning, picture processing task, and analysis
can be found in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, Supplemental Experimental
Procedures, Supplemental References, and one table and can be found with
this article online at doi:10.1016/j.cmet.2011.09.010.
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